Article PDF first page preview

First page of Endometriosis, Raynaud’s Syndrome and Migraine: A Retrospective Study of 12 Million Women

Objective: Our study focused on evaluating a possible relationship between endometriosis, Raynaud’s syndrome or migraine among women. Design: This was a cross-sectional population-based study. Participants/Materials, Setting, Methods: We used 12,684,067 hospitalized patient records in the Healthcare Cost and Utilization Project (HCUP) database between 2007 and 2014. We calculated the prevalence of endometriosis, Raynaud’s syndrome and migraine. We also evaluated the possible role of depression, anxiety and autoimmune diseases to eliminate confounding factors. Unadjusted and adjusted multivariate logistic regression were applied to evaluate the relationship between variables. Results: Unadjusted analysis revealed a strong association between endometriosis and Raynaud’s syndrome and migraine. (OR=2.491 95%CI 1.677-3.699). After adjusting for sociodemographic characteristics as well as depression and anxiety, the association remained significant (OR=1.779; 95%CI 1.166-2.716). Among younger patients aged 18–35 with endometriosis, the associations were stronger with Raynaud's Syndrome (adjusted OR = 1.61, 95% CI = 1.20–2.16) and migraine (adjusted OR = 2.59, 95% CI = 2.47–2.72). Limitations: The HCUP database is cross-sectional in nature, and hence, we could not establish the temporal relationship between endometriosis, Raynaud’s syndrome and migraine. Also, the severity of endometriosis and the treatment received by the patients were not included in the dataset, and it prevented us from investigating the role of potential confounding factors. Conclusion: Our study suggests an association between endometriosis, Raynaud’s syndrome and migraine. It is possible that these conditions share a similar mechanism possibly vascular reaction and endothelial dysfunction related to chronic inflammation.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial